Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of catechol glycoside compounds to early-stage Alzhemier's disease

A technology of catechol glycosides and compounds, which is applied in the field of medicine, can solve the problems of not being able to cure Alzheimer's disease and preventing the progress of the disease, so as to improve and cognitive function, reduce oxidative stress, and improve cognition The effect of the function

Inactive Publication Date: 2014-08-13
崔德华
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The currently approved drugs for the treatment of AD are mainly acetylcholinesterase inhibitors (AChEI) and NMDA receptor antagonists, but these drugs cannot cure Alzheimer's disease and cannot block the progression of the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of catechol glycoside compounds to early-stage Alzhemier's disease
  • Application of catechol glycoside compounds to early-stage Alzhemier's disease
  • Application of catechol glycoside compounds to early-stage Alzhemier's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1: the synthetic route of catechol glycoside compound

[0026] In the following preparations, 1 H-NMR is determined by Varian Mercury 300MHZ, and MS is determined by VG-7070. All solvents used were re-filtered, and anhydrous solvents were obtained by drying according to standard methods. The reaction was traced by TLC, and post-treatment was washed with saturated sodium bicarbonate and dried over anhydrous magnesium sulfate. Unless otherwise specified, the products were purified by column chromatography with 200-300 mesh, GF254 silica gel (Qingdao Ocean Chemical Factory) packed.

[0027] Preparation Examples:

[0028] Preparation of compound PMG:

[0029] D-anhydrous glucose 30g (167mmol), anhydrous methanol 50mL, cation exchange resin 30g, reflux for about 6h. After the reaction was complete, the resin was removed by filtration, washed with methanol several times, evaporated to dryness, and dehydrated with toluene several times to obtain 31.4 g of a whit...

Embodiment 2

[0040] Example 2: Catechol glycosides inhibit neuronal apoptosis induced by Aβ25-35

[0041] N2a cells were cultured in DMEM medium containing 10% FBS at 37°C with 5% CO 2 cell culture incubator. Cells in the logarithmic growth phase were inoculated into 96-well plates, and PMG that had been synthesized was added. The results of MTT assay showed that N2a cells were co-incubated with 25 μM Aβ25-35 for 24 hours, and the cell viability was significantly reduced. Compared with the normal control group, the difference was the largest. obvious. There is no statistical difference in cell viability between the cell group treated with the compound alone and the cells in the normal control group, indicating that 10 μM of the compound has no obvious cytotoxicity to N2a cells. When the compound (10 μM) was co-incubated with 25 μM Aβ25-35 for 24 hours, the OD value increased, the survival rate was as high as 95.29%, and the cell survival rate was significantly higher than that of the Aβ2...

experiment example 3

[0042] Experimental example 3: Effects of catechol glycosides on the inflammatory response of N2a cells induced by Aβ25-35

[0043] N2a cells were cultured in DMEM medium containing 10% FBS at 37°C with 5% CO 2 cell culture incubator. After the cells were treated with Aβ25-35 and PMG (10 μM) in the logarithmic phase, the cell dish was washed three times with PBS reagent, and 300 μl protein lysate (50 mM Tris-HCl (pH7.4), 150 mM NaCl, 1% NP-40, 0.1 %SDS) to lyse the cells and extract the protein. Separate the protein by SDS-PAGE electrophoresis, transfer to PVDF membrane, block with 5% milk / TBS at room temperature for one hour, add COX-2 primary antibody, spend four times overnight, wash with TBST reagent 5 times, each time for 5 minutes, then add HRP-labeled secondary antibody, which emits light after incubation at room temperature for 1 hour. For inflammatory factors TNF-α, PGE 2 For the detection of Aβ25-35 and PMG (10μM) treated cell supernatants were collected and trea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of catechol glycoside compounds to preclinical Alzhemier's disease (PCAD) and pre-mild cognitive impairment (Pre-MCI). The structural formula is shown in the specification. The compounds with the structural formula can be extracted from natural products or synthesized. Research results show that the compounds are capable of reducing oxidative stress level and inflammatory response in a nerve cell system, and protecting nerve cells. The provided catechol glycoside compounds are capable of substantially improving the spatial cognition capability of an AD mouse model, and have excellent effect when used as a medicine for interfering PCAD and Pre-MCI.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of a catechol glycoside compound in pre-clinical senile dementia (PCAD) and early senile mild cognitive impairment (Pre-MCI). Background technique [0002] Alzheimer's disease, also known as Alzheimer's Disease (AD), is an age-related degenerative disease of the central nervous system with multiple etiologies. At present, AD has become one of the main diseases that lead to the decline of the living standards of the elderly, and it is also a difficult problem that needs to be overcome in the field of social medical and health care. With the increase of social aging and the prolongation of life expectancy, the incidence of AD is increasing year by year. The main social background of the US government's brain plan is that brain diseases are causing an increasing medical burden. The burden of brain diseases such as AD has become the largest medical burde...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7034A61P25/28C07H15/203C07H1/00
Inventor 崔德华
Owner 崔德华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com